Orrick Advises Twist Bioscience on $140 Million Follow-On Offering


Orrick has advised San Francisco-based synthetic biology company Twist Bioscience (NASDAQ: TWST) on its $140.5 million follow-on offering of 5,339,285 shares of common stock at $28.00 per share, which includes full exercise of the underwriters’ option to purchase additional shares.

The offering closed on February 24, 2020. J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C. acted as joint book-running managers and Robert W. Baird & Co. Incorporated acted as lead manager for the offering.

In 2018, Orrick advised Twist on its initial public offering on the Nasdaq Global Select Market. Last year, Orrick advised Twist on a separate follow-on public offering of $90.6 million. The Orrick team advising Twist on its follow-on offering includes Bill Hughes, John Bautista, Melissa Frayer, Mark Nguyen and Nanette Agustines.